Allopurinol: A New Anti-Ischemic Role for an Old Drug
- 16 August 2011
- journal article
- editorial
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 58 (8), 829-830
- https://doi.org/10.1016/j.jacc.2011.02.072
Abstract
No abstract availableFunding Information
- AstraZeneca
- Boston Scientific Corporation
This publication has 18 references indexed in Scilit:
- The Anti-Ischemic Mechanism of Action of Ranolazine in Stable Ischemic Heart DiseaseJournal of the American College of Cardiology, 2010
- The Potential for Xanthine Oxidase Inhibition in the Prevention and Treatment of Cardiovascular and Cerebrovascular DiseaseCardiovascular Psychiatry and Neurology, 2009
- High-Dose Allopurinol Improves Endothelial Function by Profoundly Reducing Vascular Oxidative Stress and Not by Lowering Uric AcidCirculation, 2006
- Chronic Stable AnginaNew England Journal of Medicine, 2005
- Chronic Treatment With Allopurinol Boosts Survival and Cardiac Contractility in Murine Postischemic CardiomyopathyCirculation Research, 2004
- NicorandilDrugs, 2004
- The Antianginal Agent Trimetazidine Does Not Exert Its Functional Benefit via Inhibition of Mitochondrial Long-Chain 3-Ketoacyl Coenzyme A ThiolaseCirculation Research, 2003
- Electron Spin Resonance Characterization of Vascular Xanthine and NAD(P)H Oxidase Activity in Patients With Coronary Artery DiseaseCirculation, 2003
- Novel Myofilament Ca2+-Sensitizing Property of Xanthine Oxidase InhibitorsCirculation Research, 1998
- Angina Pectoris: Pathophysiology, Evaluation, and TreatmentAnnals of Internal Medicine, 1971